Pierre Bories
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 05, 2026
Targeted Next-Generation Sequencing of JAK2, CALR, and MPL in 10 326 Patients With Suspected Myeloproliferative Neoplasm.
Journal: American journal of hematology
Published: April 29, 2026
Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.
Journal: Bone marrow transplantation
Published: March 09, 2026
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
Journal: Bone marrow transplantation
Published: March 02, 2026
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.
Journal: HemaSphere
Published: December 05, 2025
Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.
Journal: Case reports in hematology
Published: October 13, 2025
Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.
Journal: Haematologica
Published: September 25, 2025
Plain language summary on subcutaneous administration of isatuximab in people with relapsed and/or refractory multiple myeloma.
Journal: Future oncology (London, England)
Published: July 17, 2025
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
Journal: Bone marrow transplantation
Published: June 20, 2025
Last Updated: 09/26/2026